In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 14, 2025), Rosalind Advisors, Inc. reported 31 stock positions worth $205.2 million . Its top holding was Delcath Systems (DCTH) at 14.1% of the portfolio, followed by Verastem (VSTM, 7.8% ) and Xeris Biopharma (XERS, 6.7% ). Compared with Q4 2024, it opened 7 new positions, sold out of 4, added to 9 and reduced 10. The biggest buy was a new position in Ideaya Biosciences (IDYA) and the biggest sale an exit from Chimerix (CMRX).
Location TORONTO, A6
CIK 0001622627
Portfolio Value $205.2M (Q1 2025) Holdings 31 stocks · $205.2M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q4 2024 DCTH Delcath Systems Inc. 2,900,389 $29.0M Add +9.4% VSTM Verastem Inc. 2,644,517 $15.9M Add +193.8% XERS Xeris Biopharma Holdings Inc. 2,495,986 $13.7M Reduce -19.6% MYO Myomo Inc. 2,703,661 $13.0M Reduce -9.8% IDYA Ideaya Biosciences Inc. 700,000 $11.5M New FENC Fennec Pharmaceuticals Inc. 1,782,844 $10.9M Add +41.5% URGN Urogen Pharma Ltd. 950,000 $10.5M Add +9.2% OCUL Ocular Therapeutix Inc. 1,218,700 $8.9M Add +8.0% ABEO Abeona Therapeutics Inc. 1,805,817 $8.6M Add +0.0% REPL Replimune Group Inc. 850,000 $8.3M Add +226.9% VRDN Viridian Therapeutics Inc. 595,000 $8.0M New MDWD Mediwound Ltd. 506,893 $7.9M Reduce -19.3% SVRA Savara Inc. 2,654,944 $7.4M No change VRNA Verona Pharma Ltd. 100,000 $6.3M Reduce -33.3% NSPR Inspiremd Inc. 2,274,990 $6.1M Reduce -8.8% HELP Cybin Inc. 810,918 $5.1M No change NUVB Nuvation Bio Inc. 2,451,500 $4.3M New PROF Profound Medical Corp. 692,185 $4.0M No change TRVI Trevi Therapeutics Inc. 612,901 $3.9M Reduce -42.3% PHVS Pharvaris NV 223,627 $3.5M New KALV Kalvista Pharmaceuticals Inc. 303,864 $3.5M No change PYPD Polypid Ltd. 1,018,021 $2.8M No change MIND MEDICINE MINDMED INC 420,000 $2.5M New CMPS Compass Pathways PLC 823,286 $2.4M Add +16.3% OPTINOSE INC 256,190 $2.3M Reduce -70.8% COGT Cogent Biosciences Inc. 248,285 $1.5M New TLPH Talphera Inc. 2,003,939 $992K Add +226.4% KPRX Kiora Pharmaceuticals Inc. 250,059 $753K Reduce -0.2% KURA Kura Oncology Inc. 100,000 $660K New ACOG Alpha Cognition Inc. 104,836 $530K Reduce -58.5% BFRI Biofrontera Inc. 644,393 $516K Reduce -20.6%
Options reported separately and not counted above: INVESCO QQQ TR puts ($374K), LEXICON PHARMACEUTICALS INC calls ($30K), CANDEL THERAPEUTICS INC puts ($4K).
Portfolio Sells Q4 2024 → Q1 2025 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q4 2024 % Of Portfolio Change To Portfolio ▲ CMRX Chimerix Inc. Sold out 0.00% −5.72 MYO Myomo Inc. Reduce -9.8% 6.34% −4.07 MDWD Mediwound Ltd. Reduce -19.3% 3.83% −2.19 OPTINOSE INC Reduce -70.8% 1.14% −2.01 VRNA Verona Pharma Ltd. Reduce -33.3% 3.09% −0.66 NSPR Inspiremd Inc. Reduce -8.8% 2.98% −0.55 ACOG Alpha Cognition Inc. Reduce -58.5% 0.26% −0.54 FLNA Filana Therapeutics Inc. Sold out 0.00% −0.53 TRVI Trevi Therapeutics Inc. Reduce -42.3% 1.88% −0.48 BFRI Biofrontera Inc. Reduce -20.6% 0.25% −0.23 OWLT Owlet Inc. Sold out 0.00% −0.12 KPRX Kiora Pharmaceuticals Inc. Reduce -0.2% 0.37% −0.08 RLMD Relmada Therapeutics Inc. Sold out 0.00% −0.03 XERS Xeris Biopharma Holdings Inc. Reduce -19.6% 6.68% +1.01
Portfolio Buys Q4 2024 → Q1 2025 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q4 2024 % Of Portfolio Change To Portfolio ▼ IDYA Ideaya Biosciences Inc. New 5.59% +5.59 VSTM Verastem Inc. Add +193.8% 7.77% +5.26 VRDN Viridian Therapeutics Inc. New 3.91% +3.91 REPL Replimune Group Inc. Add +226.9% 4.04% +2.34 NUVB Nuvation Bio Inc. New 2.10% +2.10 PHVS Pharvaris NV New 1.71% +1.71 MIND MEDICINE MINDMED INC New 1.20% +1.20 FENC Fennec Pharmaceuticals Inc. Add +41.5% 5.29% +1.00 COGT Cogent Biosciences Inc. New 0.72% +0.72 KURA Kura Oncology Inc. New 0.32% +0.32 TLPH Talphera Inc. Add +226.4% 0.48% +0.31 URGN Urogen Pharma Ltd. Add +9.2% 5.12% +0.13 CMPS Compass Pathways PLC Add +16.3% 1.15% −0.29 OCUL Ocular Therapeutix Inc. Add +8.0% 4.35% −0.84 ABEO Abeona Therapeutics Inc. Add +0.0% 4.19% −1.23 DCTH Delcath Systems Inc. Add +9.4% 14.13% −3.06
Options Activity Q4 2024 → Q1 2025 Security Type Change vs Q4 2024 Underlying Shares Value ▼ CASSAVA SCIENCES INC put Sold out 417,400 $3.7Mbefore exit BIOMEA FUSION INC put Sold out 910,700 $2.8Mbefore exit CORMEDIX INC call Sold out 183,900 $920Kbefore exit EDGEWISE THERAPEUTICS INC put Sold out 237,500 $808Kbefore exit ISHARES TR put Sold out 200,000 $404Kbefore exit INVESCO QQQ TR put Reduce -50.0% 50,000 $374K SPDR SERIES TRUST put Sold out 800,000 $311Kbefore exit NEUMORA THERAPEUTICS INC. put Sold out 136,600 $300Kbefore exit RELMADA THERAPEUTICS INC put Sold out 100,000 $95Kbefore exit SPDR SERIES TRUST call Sold out 1,400,000 $22Kbefore exit CANDEL THERAPEUTICS INC put Reduce -94.0% 15,800 $4K
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 29 $266.2M DCTH, FENC, XERS, SVRA, VSTM Q1 2026 32 $244.1M DCTH, XERS, FENC, SVRA, PCVX Q4 2025 29 $274.5M DCTH, SVRA, FENC, XERS, VRDN Q3 2025 29 $283.0M DCTH, CYTK, FENC, VSTM, RZLT Q2 2025 29 $206.6M DCTH, FENC, CYTK, OCUL, IDYA Q1 2025 31 $205.2M DCTH, VSTM, XERS, MYO, IDYA Q4 2024 Amended 28 $185.7M DCTH, MYO, MDWD, CMRX, XERS Q3 2024 29 $150.7M DCTH, MYO, CRMD, ABEO, MDWD Q2 2024 35 $126.5M DCTH, MYO, MDWD, OPTINOSE INC, ABEO Q1 2024 31 $106.9M MYO, LYRA, MDWD, OPTINOSE INC, XERS